Article

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancer

2026-02-09

Abstract excerpt

Recurrence scores based on a 21-gene assay are clinically useful for predicting prognosis and chemotherapy benefit in postmenopausal node-positive breast cancer patients, but its performance in premenopausal patients is inconsistent. Here, we evaluated Ataraxis Breast RISK (ATX), an AI test that predicts recurrence risk, and compared it with the genomic assay. ATX identified high risk patients misclassified as low...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9d5b4cba-eea0-5cba-a471-edd28885074c
DOI: 10.64898/2026.02.06.26345771

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancerDOI 10.64898/2026.02.06.26345771Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.Semantic proximity Read

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.Semantic proximity Read

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity Read

Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.Semantic proximity Read

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read